Kidney transplantation in patients with antibodies against donor HLA class II

H. S. Pollinger, M. D. Stegall, J. M. Gloor, S. B. Moore, S. R. Degoey, N. A. Ploeger, W. D. Park

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


The immunologic risk associated with donor-specific antibodies (DSA) against Class II human leukocyte antigens (HLA) in kidney transplant (KTx) recipients is unclear. The aim of this study was to determine the outcome of KTx when DSA was detected only against HLA Class II. To isolate the impact of anti-Class II DSA, we retrospectively analyzed 12 KTx recipients who at baseline had a positive B-cell flow cytometric crossmatch (FXM) and a negative T-cell FXM. Using alloantibody specification analysis, 58.3% (7/12) had DSA against donor Class II and 41.7% had no demonstrable DSA. Biopsy-proven AMR occurred in 57% (4/7) in the Class II+ group and 0% in the Class II- group (p > 0.05). Peritubular capillaries stained positive for C4d in 86% (6/7) of the Class II+ patients and in 40% (2/5) of the Class II - patients (p > 0.05). One patient in the Class II+ group lost their graft at 3 months to accelerated transplant glomerulopathy, while all other grafts were functioning 3-37 months posttransplant despite the persistence of anti-Class II DSA. We conclude that KTx recipients with clearly defined anti-Class II DSA are at risk for humoral rejection suggesting that desensitization and/or close posttransplant monitoring may be needed to prevent AMR.

Original languageEnglish (US)
Pages (from-to)857-863
Number of pages7
JournalAmerican Journal of Transplantation
Issue number4
StatePublished - Apr 2007


  • Class II antibody
  • Donor specific antibody
  • Flow cytometric cross match
  • Human leukocyte antigen
  • Kidney transplant
  • Positive cross match
  • Single antigen flow bead

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)


Dive into the research topics of 'Kidney transplantation in patients with antibodies against donor HLA class II'. Together they form a unique fingerprint.

Cite this